Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for Monitoring Disease Progression or Recurrence

The use of tumor markers for genetic characterization in biological samples addresses the challenge of evaluating anti-cancer treatment effectiveness by providing a sensitive and specific method for tumor detection and monitoring, enabling effective evaluation of treatment outcomes and early detection of recurrence.

Inactive Publication Date: 2015-11-19
ESOTERIX GENETIC LAB
View PDF6 Cites 61 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach provides a highly sensitive and specific method for detecting and monitoring tumors, enabling effective evaluation of treatment outcomes and early detection of recurrence, with the ability to monitor disease progression and response to therapy.

Problems solved by technology

An impediment in the development of anti-cancer modalities is the dearth of methods for evaluating the effectiveness of such treatments.
However, limitations of current surrogate endpoint validation techniques include a general failure in predicting outcome in treating diseases that are multifactorial in terms of the physiological and / or behavioral changes that may occur in populations suffering from the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Stool Sample Preparation

[0135]Sample Collection and Recovery of DNA from Stool

[0136]Stool samples may be frozen within 1 hour of defecation, and shipped on dry ice (78° C.) for processing and analysis. Once received, samples may be subjected to different stabilization and / or processing techniques.

[0137]Different sample preparation methodologies used to recover DNA from stool have been previously reported (Ahlquist D A, Skoletsky J E, Boynton K A, et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multi-target assay panel. Gastroenterology 2000; 119:1219-1227; Whitney D, Skoletsky J, Moore K, et al. Enhanced Retrieval of DNA from Human Fecal Samples Results in Improved Performance of Colorectal Cancer Screening Assay. J Mol. Diagn. 2004; 6 (4), 386-395). Stool aliquots may be weighed and combined with a stabilization buffer (e.g., 0.5M Tris, 0.15M EDTA, and 10 mM NaCl). Stabilization buffer may be added at a ratio of 7:1 volume to stool we...

example 2

Blood Sample Processing (Isolation of Free DNA)

[0138]Free-DNA may be isolated from patient blood, plasma or serum preparations over a column, e.g., a Qiagen column, followed by incubation in a hybrid-capture technique to isolate specific DNA fragments.

[0139]Plasma samples may be prepared from patient blood by collecting plasma from patient and a) centrifuging the sample (e.g. 3000 rpm for 30 min); b) transferring the plasma (being careful to not transfer any of the cells) into appropriately labeled sterilized tubes and centrifuging them again (e.g. 3,000 rpm for 30 min); c) filtering the sample through a filter that excludes cells (e.g. Millipore Ultrafree-MC 0.45 micron filter Unit) followed by another spin (e.g. 3,000 rpm for 15 min); and d) discarding the top filter and transferring the samples to appropriately labeled cryovials stored at −20° C.

[0140]Serum samples may be prepared from patient blood by: a) collecting a clotted serum sample from a patient and spinning it down (e.g...

example 3

Human DNA Purification

[0141]Target human DNA fragments may be purified from total nucleic acid preparations using a DNA affinity electrophoresis purification methodology. In brief, human DNA can be separated from the excess bacterial DNA by hybridization of the target sequences to complementary, covalently-bound oligonucleotide capture probes in acrylamide gels membranes. Crude human DNA preparations (2400 μl) may be mixed with 960 μl formamide (Sigma), 385 μl 10×TBE, and filtered through a 0.8 μm syringe filter (Nalgene, Rochester, N.Y.), then denatured (heated at 95 C for 10 min., then cooled in ice for 5 min.). The sample mix may be loaded on top of a capture membrane, and electrodes above and below the capture layer may be applied. Samples may be electrophoresed (15V, 16 h) using TBE in the reservoirs above and below the capture layer. After electrophoretic capture the remaining solution may be removed from the tubes, and the tube array may be separated from the capture plate. T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sensitivityaaaaaaaaaa
sensitivityaaaaaaaaaa
sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention provides methods for detecting and monitoring diseases associated with genetic abnormalities in a subject.

Description

RELATED APPLICATIONS[0001]This application claims priority to and is a continuation of U.S. patent application Ser. No. 11 / 666,561, filed on Feb. 4, 2008, which claims priority to and is a national stage filing under 35 U.S.C. §371 of PCT International application PCT / US2005 / 039670 designating the United States of America, and filed Oct. 27, 2005, the entire contents of which are hereby incorporated herein by reference. This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60 / 627,248, filed on Nov. 12, 2004, and U.S. Provisional Application No. 60 / 623,005, filed on Oct. 27, 2004, the entire contents of both of which are hereby incorporated herein by reference.FIELD OF THE INVENTION[0002]The invention relates generally to methods for detecting and monitoring diseases using nucleic acid-based markers.BACKGROUND OF THE INVENTION[0003]An impediment in the development of anti-cancer modalities is the dearth of methods for evaluating the effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68A61B5/00
CPCC12Q1/6886A61B5/4842C12Q2600/156C12Q2600/112A61B5/4848C12Q2600/118C12Q2600/154Y10T436/145555
Inventor SHUBER, ANTHONY P.
Owner ESOTERIX GENETIC LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com